Ryan White Care Hepatitis C & B Language
NATAP Webinars
HIV Treatment Strategies & Prevention
Fri, June 20, 2025 12:30 PM EDT
Click here to Register
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
Doravirine-Based ART
- (07/02/25)
Islatravir Metabolic, Kidney, Lipids
- (07/02/25)
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
- (06/24/25)
Treatment With Temsavir Improves the Recognition of HIV-1–Infected Cells by Broadly Neutralizing Antibodies
- (06/02/25)
Lifestyle modification (diet) programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial
- (06/02/25)
Neuropathogenesis of acute HIV: mechanisms, biomarkers, and therapeutic approaches, review
- (06/02/25)
Nonpharmacologic interventions [exercise] to improve quality of life of older adults with HIV
- (06/02/25)
Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort
- (06/02/25)
HIV RNA testing to monitor oral PrEP use does not add clinical value: a real-world cohort study-United States, 2019-2023
- (06/02/25)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
EASL:
Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across Europe
- (05/23/25)
EASL:
Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study
- (05/20/25)
EASL:
A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients
- (05/20/25)
More Hep D Articles...
Aging & Perinatally Acquired HIV
CROI:
Thwarting a protein in the hope of a better quality of life: fostemsavir gp120 aging study
- (04/07/25)
CROI:
Plasma Inflammation is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV
- (03/24/25)
More Aging & HIV Articles...
PrEP
CROI:
The Influence of Racialized Economic Segregation on Unmet HIV prevention Needs in the Real World
- (03/29/25)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
EASL:
Pharmacokinetics of Bemnifosbuvir in Participants With Renal Impairment
- (05/20/25)
EASL:
No DDI Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide
- (05/20/25)
EASL:
Pharmacokinetics of Bemnifosbuvir in Participants with Hepatic Impairment
- (05/20/25)
EASL:
Efficacy and Safety of Bemnifosbuvir and Ruzasvir After 8 Weeks of Treatment in Patients With Chronic Hepatitis C Virus (HCV) Infection
- (05/20/25)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
EASL:
A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients
- (05/20/25)
EASL:
EASL Clinical Practice Guidelines Hepatitis B
- (05/21/25)
EASL:
Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
- (05/21/25)
EASL:
Viral kinetics and sequence analysis of a Phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
- (05/21/25)
EASL:
First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models
- (05/21/25)
EASL:
Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small molecule PD-L1 inhibitor, in healthy and chronic hepatitis B (CHB) subjects
- (05/21/25)
More Hep B Articles...
Fatty Liver, NAFLD, NASH
Is coming off semaglutide slowly the key to preventing weight regain?
- (06/02/25)
Lifestyle modification (diet) programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial
- (06/02/25)
EASL:
Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo
- (05/19/25)
EASL:
Exercise partly protects against semaglutide-induced muscle loss in obese LDLR-/-.Leiden mice
- (05/19/25)
EASL:
Efimosfermin Alfa Once-Monthly Treatment Improves Collagen Biomarker Profiles and Rapidly Induces Histological Fibrosis Regression in Subjects with MASH Stage F2-F3 Fibrosis in a 24-week Phase 2 Trial
- (05/19/25)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
https://academicmedicaleducation.com/meeting/2nd-african-workshop-women-hiv-2025
https://academicmedicaleducation.com/meeting/2nd-menopause-hiv-webinar-2025
https://www.croiconference.org
https://academicmedicaleducation.com/meeting/15th-international-workshop-women-hiv-2025
https://acthiv.org/
https://ddw.org/
https://www.easlcongress.eu/
https://asm.org/Events/ASM-Microbe/Home
IAS 2025, the 13th IAS Conference on HIV Science,
Kigali, Rwanda, July 13 to 17,
pre-conferences on 13 July.
https://www.iasociety.org/conferences/ias2025
https://academicmedicaleducation.com/meeting/26th-international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs
https://academicmedicaleducation.com/meeting/11th-international-viral-hepatitis-elimination-meeting-ivhem-2025
https://academicmedicaleducation.com/meeting/8th-conference-liver-disease-africa-colda-2025
https://www.eacsociety.org/european-aids-conference/european-aids-conference/
https://idweek.org/
https://academicmedicaleducation.com/meeting/16th-international-workshop-hiv-aging-2025
https://www.aasld.org/the-liver-meeting
https://neurohiv.com/
